Background: When the Ra-223 phase 3 clinical trial (ALSYMPCA) was conducted, Abi was not available; REASSURE is a prospective, observational clinical study of Ra-223 in pts with mCRPC with a 7-year follow-up (NCT02141438). Pts could have had antihormonal agents, such as Abi, prior to receiving Ra-223. The objective of this interim review was to evaluate the fractures and skeletal-related events (SREs) based on prior Abi and the use of BHAs, denosumab and bisphosphonates. Methods: Descriptive statistics were generated for baseline characteristics, fractures, SREs and overall survival (OS) by BHA use in pts who had completed Abi treatment prior to receiving Ra-223 (prior Abi) or who had no prior Abi (Abi-naïve). An SRE was defined as any skeletal-related adverse event or any radiotherapy to bone. Results: As of Nov 2017, 1439 pts were enrolled, with a median follow-up time of 9.1 months. 708 (49%) pts had received BHAs at baseline, and BHAs were given concomitantly with Ra-223 in 553 (38%) pts. 430 (30%) pts received prior Abi, and Ra-223 was given as second line in 37% (157/430) of those pts; 705 (49%) pts were considered Abinaïve. For the prior Abi group, median time of exposure to Abi was 11 months. In the prior Abi group SREs occurred in 17% and 22% of pts, with and without BHAs, respectively. In the Abi-naïve group, 16% of pts had SREs regardless of BHA use. Fractures were reported in 7/430 pts (1.6%) in the prior Abi group. In the Abi-naïve group fractures were reported in 2/311 (1%) and 8/394 (2%) pts with and without BHAs, respectively (Table) .
Conclusions: BHAs were under-utilised in this study despite several guidelines and recommendations. The rate of fracture was the same in those who were Abi-naïve compared with those who received Abi prior to Ra-223. Pts with prior Abi had a shorter OS; these pts received Ra-223 at a later time during their disease course, as reflected by a longer time from CRPC to Ra-223 initiation. Clinical trial identification: NCT02141438. 
